TRACON Pharmaceuticals Announces Updated Positive Results from Clinical Trial

TRACON Pharmaceuticals (NASDAQ:TCON) is a clinical stage biopharmaceutical company that develops and commercializes novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases. The company reported that it has updated positive results from a Phase 1b clinical trial combining TRC105 with Inlyta® (axitinib) in patients with advanced or metastatic renal cell carcinoma (RCC).

According to the press release:

The open-label dose escalation and expansion Phase 1b study enrolled patients who had received at least one prior line of therapy with a VEGF receptor tyrosine kinase inhibitor (VEGFR TKI).  The median number of prior therapies was three (range of one to six). All patients in the trial received a combination of TRC105 and Inlyta.

Click here to read the full press release.